

The Source

Lindner Center
of HOPE



PSYCHIATRY AND PSYCHOLOGY NEWS FOR MENTAL HEALTH PROFESSIONALS

DECEMBER 2013



Events

January 7

noon - 1:00 p.m.

Lindner Center of HOPE Grand Rounds

Clinical Applications of Positive Psychology,

Ryan M. Niemiec, Psy.D. and Richard F. Reckman, Ph.D.

January 8

6:30 to 7:30 pm

Mason Community Center

Evening with the Experts: Work life balance:

Organize and plan your life Presented by
Melissa McCarthy, MS, CRC, CPRP, Lindner Center
of HOPE Life Skills Development Coach

January 21

Scott Bullock, MSW, LISW-S, and Anna Guerdjikova,
PhD, MSW, LSW, present to Jewish Family Services
Social Workers

January 23

The Luxe Hotel

Paul Keck, MD, Lindner Center of HOPE President
and CEO, presents in Los Angeles at Bridges to
Recovery Lunch and Learn

Read more about events at
lindnercenterofhope.org/events

Patient Satisfaction

Patient Satisfaction results for November
2013 averaged a rating of **4.46 out of 5**,
with 5 signifying the best possible care.



Lead Investigator, Dr. Susan McElroy: Positive Top-line Results Shown for Vyvanse® Capsules in Adults with Binge Eating Disorder

Shire plc (LSE: SHP, NASDAQ: SHPG) announced positive top-line results from two identically designed randomized placebo-controlled Phase 3 studies evaluating the efficacy and safety of Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) versus placebo in adults with binge eating disorder (BED) in November. In both studies Vyvanse was found to be statistically superior to placebo on the primary efficacy analysis (p-value <0.001) of the change from baseline at weeks 11 to 12 in terms of number of binge days per week. The safety for Vyvanse in these two studies appears to be generally consistent with the known profile established in studies in adults with Attention-Deficit/Hyperactivity Disorder (ADHD). The Company is reporting the data sooner than originally anticipated because of faster than expected completion of both studies.

"Binge eating disorder is an important public health problem that is under-recognized, and causes great distress for patients," said Susan L. McElroy, M.D., Lindner Center of HOPE Chief Research Officer, Professor of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine; and principal investigator of both studies. "Increased awareness of binge eating disorder among the medical community is greatly needed, as are novel

treatment strategies for individuals suffering from this often secretive disorder."

"We are extremely pleased with these results, and will be working expeditiously to submit an application to the U.S. Food and Drug Administration for a new indication of BED for Vyvanse, already well established for its efficacy and safety in ADHD," said Flemming Ornskov, M.D., Chief Executive Officer, Shire. "BED is a condition for which there is no currently approved pharmacologic treatment and yet there is significant unmet patient need, as was demonstrated with the faster than expected enrollment of participants in our clinical trial program. Our development of Vyvanse for BED also aligns well with Shire's growth strategy of developing innovative treatments to address significant unmet patient needs."

The Research Institute at Lindner Center of HOPE will be a site for the continuation study starting in January. It will be a Phase 3 Multicenter, Double-blind, Placebo-controlled, Randomized withdrawal Study to Evaluate the Maintenance of Efficacy of SPD489 in Adults Aged 18-55 Years with Moderate to Severe Binge Eating Disorder.

For more information log on to: [lindnercenterofhope.org/News/NewsDetail/sni\[393\]/234](http://lindnercenterofhope.org/News/NewsDetail/sni[393]/234)

In The News

Lindner Center of HOPE Chief Research Officer Co-Authors Manuscript Published in *Molecular Psychiatry*

Article connects higher body mass index and increased metabolic comorbidity with bipolar disorder

Lindner Center of HOPE's Chief Research Officer, Susan L. McElroy, MD, has co-authored a manuscript published in *Molecular Psychiatry* December 10, 2013. The article states that bipolar disorder is associated with higher body mass index (BMI) and increased metabolic comorbidity.

To investigate the genetic factors underlying bipolar disorder while considering BMI, a genome-wide analyses was conducted using data from the Genetic Association Information Network Bipolar Disorder study. Specifically, 729,454 genotyped SNP markers on 388 European American BD cases and 1020 mentally healthy controls were analyzed with available data for maximum BMI. A genome-wide association analyses of the genetic effects while accounting for the effect of maximum BMI was conducted, and SNP-BMI interactions were also evaluated.

A joint test of main and interaction effects demonstrated significant evidence of association at the genome-wide level with rs1277242 in an intron of TCF7L2 ($p=2.85E-8$). This SNP exhibited interaction effects, indicating that the bipolar susceptibility risk associated with this SNP was dependent on BMI. TCF7L2 codes for the transcription factor TCF/LF, part of the Wnt canonical pathway, and is one of the strongest genetic risk variants for Type 2 Diabetes (T2D). This finding is consistent with bipolar disorder pathophysiology, as the Wnt pathway has crucial implications in neurodevelopment, neurogenesis and neuroplasticity, and is involved in the mechanisms of action of BD and depression treatments. The hypothesis is that genetic risk for bipolar disorder is BMI-dependent, which may be related to common genetic risk with Type 2 Diabetes.

More details can be found in *Molecular Psychiatry*.

The Research Institute at Lindner Center of HOPE Update

Research Institute Recognized by NIMH National E-Newsletter for Promoting Clinical Research

After staff members from The Research Institute at Lindner Center of HOPE worked with Mental Health America of Northern Kentucky and Southwest Ohio (MHANKSO) to produce a cable show to increase understanding about the importance of clinical research, National Institute of Mental Health (NIMH) recognized the organizations for efforts to educate the public in its national e-newsletter. The show is available on MHANKSO's YouTube Channel.

Save the Date...

5th Annual Touchdown for HOPE Super Bowl XLVIII February 2, 2014 – Great American Ballpark

Benefitting Bipolar and Mood Disorders Research at Lindner Center of HOPE Anthony and Dede Muñoz will greet fans of Lindner Center of HOPE for Super Bowl XLVIII on Sunday, February 2nd at Great American Ball Park. The 5th annual Super Bowl party benefiting Lindner Center of HOPE promises once again to be The Best Super Bowl Party In Town!

A special VIP reception will be held for all sponsors of the event from 4:30 p.m. to 5:30 p.m. in the Ballpark's Hall of Fame. Touchdown ticket holders will arrive for a tailgate party beginning at 5:30 p.m. in the Champions Club, with kick-off set for 6:30 p.m.

Tickets prices are: \$100/person - \$75/Young Professional.

All tickets include food, drinks, and free parking in the Riverfront Parking Garage. Cincinnati favorites include Montgomery Inn riblets, LaRosa's pizza, Skyline coneys, and United Dairy Farmer ice cream to name a few.

To make your reservation, please contact Jenny Southers in the Development Office at (513) 536-0323 - or register online at: www.lindnercenterofhope.org



lindnercenterofhope.org

(513) 536-HOPE (4673)

Lindner Center
of HOPE |  UC Health™

4075 Old Western Row Rd.
Mason, OH 45040
(888) 536-HOPE (4673)

**Interested in touring
Lindner Center of HOPE?**
Contact Katie Hamm at (513) 536-0324.

Follow us on

